Pilatus Biosciences Inc. Secures FDA Orphan Drug Designation for PLT012: A Breakthrough in Liver and Intrahepatic Bile Duct Cancer Treatment
DOVER, Del. and EPALINGES, Switzerland, Dec. 11, 2024 /PRNewswire/ -- Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver...
J.F. Lehman & Company Raises $2.2 Billion for Oversubscribed Fund VI
NEW YORK, Dec. 11, 2024 /PRNewswire/ -- J.F. Lehman & Company ("JFLCO"), a leading middle-market private equity firm focused exclusively on the aerospace, defense, maritime, government and environmental sectors, today announced the successful...
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
MinIO Research Reveals the Impact of AI on Storage Infrastructure
IT leaders see object storage as the foundation for AI and advanced analytic workloads REDWOOD CITY, Calif., Dec. 10, 2024 /PRNewswire/ -- MinIO, the leader in high-performance object storage, today announced the findings of its Object Storage and...
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for...
AQUASTRONG Unveils Comprehensive Pool Circulation System Solutions: From Filtration to Heating
HONG KONG, Dec. 10, 2024 /PRNewswire/ -- AQUASTRONG today announced the launch of its upgraded pool circulation system solutions, further expanding its product line to meet the diverse needs of pool users. Leveraging innovative technology and an...
Vodafone Idea selects Tejas Networks to scale its backhaul capacity for 4G and 5G rollouts
BENGALURU, India, Dec. 10, 2024 /PRNewswire/ -- Tejas Networks (BSE: 540595) (NSE: TEJASNET) today announced that it has entered into a three - year contract with Vodafone Idea Limited ("VIL"), a leading telecom service provider in India, to supply...